Annual Reports in Medicinal Chemistry

Erscheinungsjahr 2014
ISBN: 978-0-12-800167-7
Verlag: William Andrew Publishing

Buch, Englisch, 636 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 960 g

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry with an emphasis on emerging topics in the biological sciences that are expected to provide the basis for entirely new future therapies.

Zielgruppe

<p>Ideally suited for chemists engaged in multidisciplinary teams for drug discovery; this includes medicinal chemists and others involved in chemical biology and bio-organic disciplines and computational chemistry</p>

Fachgebiete

• Naturwissenschaften Chemie Organische Chemie Biochemie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Biochemie (med.)

Inhaltsverzeichnis

- A Personal Essay: My Experiences in the Pharmaceutical Industry
- Adventures in Medicinal Chemistry - A Career in Drug Discovery
- Natural and Synthetic Neuroactive Steroid (NAS) Modulators of GABAA and NMDA Receptors
- Development of LRRK2 Kinase Inhibitors for Parkinson's Disease
- Stimulating Neurotrophin Receptors in the Treatment of Neurodegenerative Disorders
- Small Molecule Modulators of GPR40 (FFA1)
- Recent Advances in the Development of P2Y12 Receptor Antagonists as Antiplatelet Agents
- Current Approaches to the Treatment of Atrial Fibrillation
- Advances in the Discovery of Small Molecule IRAK4 Inhibitors
- H4 Receptor Antagonists and Their Potential Therapeutic Applications
- Urate Crystal Deposition Disease and Gout - New Therapies for an Old Problem
- p53 - MDM2 and MDMX Antagonists
- Modulators of Atypical Protein Kinase C as Anticancer Agents
- Advancement of Cell Wall Inhibitors in Mycobacterium Tuberculosis
- Nucleosides and Nucleotides for the Treatment of Viral Diseases
- Advances in Inhibitors of Penicillin Binding Proteins and ß-lactamases as Antibacterial Agents
- Tumor Microenvironment as Target in Cancer Therapy
- Novel Screening Paradigms for the Identification of Allosteric Modulators and /or Biased Ligands for Challenging G-Protein-Coupled Receptors (GPCRs)
- Mer Tyrosine Kinase Receptor: Therapeutic Opportunities in Oncology, Virology and Cardiovascular Indications
- Disease Modifying Agents for the Treatment of Cystic Fibrosis
- Advancements in Stapled Peptide Drug Discovery and Development
- Cytochrome P450 Enzyme Metabolites in Lead Discovery and Development
- Case History: ForxigaTM (Dapagliflozin), a Potent Selective SGLT2 Inhibitor for Treatment of Diabetes
- Case History: Kalydeco® (VX-770, Ivacaftor), a CFTR Potentiator for the Treatment of Patients with Cystic Fibrosis and the G551D-CFTR Mutation
- Case History: XeljanzTM (Tofacitinib Citrate), A First-In-Class Janus Kinase (JAK) Inhibitor for the Treatment of Rheumatoid Arthritis
- New Chemical Entities Entering Phase III Trials in 2013
- To Market, To Market - 2013